Immunoassay

The Right Assay Format.
Every Modality. Every Phase.

GxP-validated ligand binding assays across the full spectrum of biologics, from mAbs and ADCs to gene therapy and biosimilars.

Talk To Us Now

Services:

  • Assay development, validation and sample analysis
  • Supporting PK/TK studies
  • De novo and kit-based biomarker assay implementation
  • Target capture, anti-drug Ab capture, Ab Sandwich assays

Therapeutic Modalities:

  • Monoclonal antibodies (mAbs)
  • Antibody fragments (Fab, nanobody, domain Abs)
  • Antibody drug conjugates (ADCs)
  • Proteins
  • Peptides
  • Bispecifics
  • Biosimilars
  • AAVs, gene therapy

Technologies:

  • ELISA (absorbance, luminescence, fluorescence)
  • GyroLab xPand, xPlore™
  • Quanterix (HDX Simoa)
  • Electrochemiluminescence (MSD Sector Imager 6000, QuickPlex)
  • Luminex (Magpix, Flexmap 3D)
  • Flow cytometry (Beckman Coulter CytoFLEX)
  • qPCR (QuantStudio™ 7) and Hybridization ELISA
  • Luminex Flexmap 3D
  • Protein Simple Ella
  • Thermo Scientific NanoDrop
  • Hamilton STAR Robotics

Reach out to us directly to learn more about Resolian’s Immunoassay services.

Start here

Ready to advance your ligand binding assay program?

Partner with a global immunoassay specialist that brings the platform breadth, regulatory expertise,
and scientific depth to deliver reliable data from pre-clinical through late-phase clinical trials..

start your project today

Our Bioanalytics Resources

Blog, Videos

Advancing Immunoassay Method Development and Automation at Resolian

Learn more

Blog

Immunoassay Pharmacokinetics

Learn more

Blog

How to Build a Comprehensive Response to Client Needs as a CRO

Learn more

Case Studies

Development and Validation of Immunogenicity Assays for ADCs

Learn more

Case Studies

Development and Validation of an Immunogenicity Assay for Detection of Anti-AAV Antibodies

Learn more

Case Studies

Challenges of Developing an ADA Assay for Bispecific Antibody Therapeutics and ADA Characterization

Learn more
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.